Published on
May 25, 2026
Saying Goodbye To The XOMA Royalty PFDs
Summary Ligand Pharmaceuticals Incorporated will acquire XOMA Royalty Corporation for $39.00 per share in cash, totaling approximately $739 million. XOMA shareholders will receive a Contingent Value Right, or CVR, for 75% of net proceeds from certain …
Source:
Seeking Alpha
-
Indeterminate
